Article Details
Retrieved on: 2024-05-13 19:23:34
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing .
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here